| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2019 | BCRX Biocryst Pharmaceuticals Inc | Aselage Steve80 | Director | Buy | 3,000 | $3.57 | $10,710.00 | +150.0% | |
| May 21, 2019 | ETON Eton Pharmaceuticals, Inc. | Brynjelsen Sean | President &CEO | Buy | 10,000 | $7.93 | $79,325.86 | +0.5% | |
| May 20, 2019 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 16,827 | $23.89 | $401,939.82 | -2.6% | |
| May 20, 2019 | TEVA Teva Pharmaceutical Industries Ltd | De Notaristefani Carlo | Executive VP Global Operations | Sell | 16,070 | $11.42 | $183,519.40 | -32.4% | |
| May 17, 2019 | AMRN Amarin Corp Plc\uk | Stack David M67 | Director | Sell | 13,174 | $18.00 | $237,138.59 | -100% | |
| May 17, 2019 | ZTS Zoetis Inc. | David Glenn | Chief Financial Officer | Sell | 8,191 | $102.22 | $837,284.02 | -43.7% | |
| May 17, 2019 | ANIP Ani Pharmaceuticals Inc | Marken James G.47 | SVP Ops &Prod Dev | Sell | 8,907 | $70.67 | $629,457.69 | -12.7% | |
| May 17, 2019 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 9,750 | $7.65 | $74,595.00 | -3.7% | |
| May 16, 2019 | BMY Bristol Myers Squibb Co | Santiago Karen Murphy | Controller | Sell | 3,065 | $47.56 | $145,771.40 | -50.0% | |
| May 16, 2019 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 66,667 | $80.13 | $5,341,893.38 | -10.5% | |
| May 16, 2019 | TEVA Teva Pharmaceutical Industries Ltd | De Notaristefani Carlo | Executive VP Global Operations | Sell | 629 | $11.76 | $7,397.04 | -3.2% | |
| May 16, 2019 | BMY Bristol Myers Squibb Co | Samuels Theodore R. II51 | Director | Buy | 5,000 | $47.29 | $236,440.00 | +22.7% | |
| May 15, 2019 | ANIP Ani Pharmaceuticals Inc | Haughey Thomas | Director | Buy | 2,500 | $69.30 | $173,240.00 | +65.9% | |
| May 15, 2019 | AMRX Amneal Pharmaceuticals, Inc. | Bhadauria Pradeep | SVP, Chief Scientific Officer | Buy | 7,000 | $8.48 | $59,360.00 | +1,400% | |
| May 15, 2019 | COLL Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Director | Sell | 25,000 | $12.84 | $321,041.63 | -6.3% | |
| May 15, 2019 | LNTH Lantheus Holdings, Inc. | Markison Brian A64 | Director | Sell | 5,000 | $24.75 | $123,754.50 | -6.9% | |
| May 15, 2019 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 11,750 | $7.81 | $91,710.00 | -4.3% | |
| May 15, 2019 | ANIP Ani Pharmaceuticals Inc | Przybyl Arthur | President And CEO | Sell | 30,000 | $70.07 | $2,102,177.15 | -4.5% | |
| May 14, 2019 | ZTS Zoetis Inc. | Lewis Clinton A. Jr.46 | Executive Vice President | Sell | 6,123 | $101.90 | $623,933.70 | -11.8% | |
| May 14, 2019 | ANIP Ani Pharmaceuticals Inc | Marken James G.47 | SVP Ops &Prod Dev | Sell | 4,917 | $70.31 | $345,714.27 | -6.6% | |
| May 13, 2019 | AMRX Amneal Pharmaceuticals, Inc. | Boyer Andrew S | Exec VP, Comm Optns | Buy | 19,000 | $9.46 | $179,740.00 | +184.4% | |
| May 13, 2019 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 34,547 | $75.51 | $2,608,813.25 | -19.6% | |
| May 13, 2019 | ANIP Ani Pharmaceuticals Inc | Schrepfer Robert W | SVP - New Bus Dev &Spec Sales | Sell | 2,409 | $71.13 | $171,352.17 | -4.1% | |
| May 13, 2019 | ELAN Elanco Animal Health Inc | Bilbrey John P49 | Director | Buy | 7,750 | $32.39 | $251,022.50 | New | |
| May 13, 2019 | ZTS Zoetis Inc. | Peck Kristin C66 | Executive Vice President | Sell | 11,500 | $100.92 | $1,160,580.00 | -21.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.